undamentalytics Newsletter
Sign in

Generate Biomedicines, Inc. (GENB) stock

Add to watchlist

Add holding +

NASDAQ: GENB Nasdaq Biotechnology Next results ~November 5, 2026

Generate Biomedicines, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders6 buying, 1 selling7 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds65 adding, 23 cuttingOf 21 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Generate Biomedicines, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 87% and a beta of 1.6 against the S&P 500.
  • Heavily shorted. 11.9% of the shares available to trade are sold short (7.4 days of average volume to cover).

Latest results

Earnings per share
-$0.52 against an average estimate of -$0.49: missed by 5.6%
Share reaction
-1.0% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.55

Generate Biomedicines' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-8.6%
  • 1 week+7.0%
  • 1 month-3.5%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Generate Biomedicines, Inc. valuation models and calculator

No model value for Generate Biomedicines, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $8m and EPS of −$0.55 (range −$0.67 to −$0.44) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.30 — $30m —
Next −$2.28 +1% $24m −20%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.7% on 90 days ago. In the last 30 days, 2 analysts raised Generate Biomedicines, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Generate Biomedicines, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.24 Current fiscal year, 60 days ago: −$2.35 Current fiscal year, 30 days ago: −$2.30 Current fiscal year, 7 days ago: −$2.30 Current fiscal year, Now: −$2.30 −$2.30 Next fiscal year, 90 days ago: −$2.06 Next fiscal year, 60 days ago: −$2.28 Next fiscal year, 30 days ago: −$2.28 Next fiscal year, 7 days ago: −$2.28 Next fiscal year, Now: −$2.28 −$2.28

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.24−$2.06
60 days ago −$2.35−$2.28
30 days ago −$2.30−$2.28
7 days ago −$2.30−$2.28
Now −$2.30−$2.28

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.49 −$0.52 −5.6%
Mar 2026 −$0.51 −$1.07 −111.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026246
  2. Sep 2026246
  3. Aug 2026246

Counts of recommendations published by analysts covering Generate Biomedicines, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.9%
of tradable shares
Days to cover
7.37
at average volume
Short interest, 1 month
+24%
to October 15, 2026
Held by institutions
82%
of shares
Held by insiders
14.0%
of shares
Employees
312
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
−11.6%
vs 200-day average
—
Volatility (1 year)
87%
Beta vs S&P 500
1.60

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
0 up, 2 down
typical move ±5.8%
After a week
2 up, 0 down
typical move ±2.4%
After a month
1 up, 1 down
typical move ±14.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −1.0% +0.5% +3.7% +13.1%
May 7, 2026 −10.7% +0.5% +1.1% −16.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$1.7B
Institutions reporting
86
Shares held vs prior quarter
▲ 7.8%
Positions opened / closed
41 / 13

Top buyers and sellers, Q2 2026: 65 institutions bought and 23 sold ; the biggest buyer was Blackrock, Inc (+1.7M shares) and the biggest seller Jpmorgan Chase & Co (−1.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Flagship Pioneering, LLC $1.1B 62.7M 62.6% 0.0%
FMR LLC $88.1M 5.2M 5.2% ▲ 23.8%
Capital World Investors $71.1M 4.2M 4.2% ▲ 5.3%
Braidwell LP $55.4M 3.3M 3.3% ▼ 8.6%
Price T Rowe Associates Inc $36.4M 2.2M 2.2% ▲ 2.2%
Norges Bank $35.3M 2.1M 2.1% —
Arch Venture Management, LLC $32.8M 1.9M 1.9% 0.0%
Harbourvest Partners LLC $29.1M 1.7M 1.7% 0.0%
Blackrock, Inc. $28M 1.7M 1.7% New
Baker Bros. Advisors LP $24M 1.4M 1.4% 0.0%
Jpmorgan Chase & Co $23.8M 1.4M 1.4% ▼ 52.2%
Deep Track Capital, LP $22.5M 1.3M 1.3% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Generate Biomedicines, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $50.3M 7 trades by 6 insiders, last 12 months Insider sales History → $16,000 1 trade by 1 insider · 100% under pre-set plans
Net ▲ $50.3M net buying
Insider Date Trade Shares Price Value
Arnold Frances Director September 1, 2026 Sell pre-set plan 1,000 $16.00 $16,000
Nally Michael Chief Executive Officer March 4, 2026 Buy 20,000 $12.00 $240,000
Flagship Pioneering Fund Vi, L.P. 10% owner March 2, 2026 Buy 1,562,500 $16.00 $25M
Mendillo Jane L Director March 2, 2026 Buy 1,500 $16.00 $24,000
Nutritional Health Ltp Fund General Partner Llc 10% owner March 2, 2026 Buy 1,562,500 $16.00 $25M
Silvers Jason President & CFO March 2, 2026 Buy 500 $16.00 $8,000
Silvers Jason President & CFO March 2, 2026 Buy 1,000 $16.00 $16,000
Grous Beth Chief People Officer March 2, 2026 Buy 300 $16.00 $4,800

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 6, 2026
  • May 7, 2026

Recent SEC filings

Data status

When each part of this page on Generate Biomedicines, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Generate Biomedicines, Inc. in brief

What does Generate Biomedicines, Inc. do?
Generate Biomedicines, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Generate Biomedicines, Inc.'s stock ticker?
Generate Biomedicines, Inc. trades under the ticker GENB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Generate Biomedicines, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Flagship Pioneering, LLC, FMR LLC and Capital World Investors. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Generate Biomedicines, Inc. stock?
Over the last 12 months, Generate Biomedicines, Inc.'s directors and officers reported 7 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Generate Biomedicines, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Generate Biomedicines, Inc. announces its own schedule.